Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 200 | 2024 | 21162 | 4.590 |
Why?
|
Mastectomy, Segmental | 60 | 2023 | 974 | 3.310 |
Why?
|
Radiotherapy, Adjuvant | 35 | 2024 | 1788 | 3.160 |
Why?
|
Mastectomy | 41 | 2024 | 1861 | 2.920 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 34 | 2021 | 934 | 1.740 |
Why?
|
Neoplasm Recurrence, Local | 94 | 2024 | 9407 | 1.720 |
Why?
|
Lymph Node Excision | 22 | 2023 | 1267 | 1.440 |
Why?
|
Carcinoma in Situ | 18 | 2016 | 784 | 1.350 |
Why?
|
Carcinoma, Ductal, Breast | 20 | 2016 | 1097 | 1.200 |
Why?
|
Lymph Nodes | 20 | 2024 | 3468 | 1.170 |
Why?
|
Radiation Injuries | 12 | 2017 | 1195 | 1.110 |
Why?
|
Mammaplasty | 10 | 2024 | 1268 | 1.050 |
Why?
|
Radiotherapy, Conformal | 9 | 2014 | 545 | 1.020 |
Why?
|
Combined Modality Therapy | 97 | 2019 | 8540 | 0.910 |
Why?
|
Axilla | 22 | 2023 | 622 | 0.780 |
Why?
|
Lymphatic Metastasis | 44 | 2024 | 2901 | 0.770 |
Why?
|
Lymphatic Irradiation | 5 | 2024 | 115 | 0.720 |
Why?
|
Brachytherapy | 8 | 2017 | 1221 | 0.680 |
Why?
|
Radiation Oncology | 9 | 2017 | 572 | 0.640 |
Why?
|
Radiotherapy | 18 | 2019 | 1497 | 0.620 |
Why?
|
Dermatomyositis | 1 | 2021 | 259 | 0.600 |
Why?
|
Neoplasm Staging | 55 | 2020 | 11218 | 0.580 |
Why?
|
Aromatase Inhibitors | 4 | 2022 | 519 | 0.550 |
Why?
|
Practice Guidelines as Topic | 6 | 2018 | 7430 | 0.530 |
Why?
|
Chemotherapy, Adjuvant | 28 | 2016 | 3552 | 0.520 |
Why?
|
Patient Satisfaction | 5 | 2015 | 3485 | 0.510 |
Why?
|
Female | 218 | 2024 | 396532 | 0.500 |
Why?
|
Sentinel Lymph Node Biopsy | 8 | 2023 | 734 | 0.490 |
Why?
|
Tamoxifen | 14 | 2015 | 967 | 0.480 |
Why?
|
Bone Neoplasms | 3 | 2023 | 2561 | 0.470 |
Why?
|
Fluorouracil | 10 | 2005 | 1652 | 0.470 |
Why?
|
Radiotherapy Dosage | 23 | 2020 | 2916 | 0.450 |
Why?
|
Mastectomy, Radical | 3 | 2003 | 19 | 0.450 |
Why?
|
Humans | 243 | 2024 | 766812 | 0.420 |
Why?
|
Antineoplastic Agents, Hormonal | 9 | 2019 | 1536 | 0.400 |
Why?
|
Breast | 10 | 2023 | 1972 | 0.370 |
Why?
|
Meta-Analysis as Topic | 6 | 2022 | 1365 | 0.360 |
Why?
|
Deglutition Disorders | 1 | 2017 | 640 | 0.360 |
Why?
|
Cyclophosphamide | 9 | 2012 | 2234 | 0.360 |
Why?
|
SEER Program | 6 | 2013 | 1444 | 0.360 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 27 | 2012 | 11876 | 0.350 |
Why?
|
Mastectomy, Modified Radical | 3 | 2000 | 62 | 0.340 |
Why?
|
Wound Healing | 1 | 2021 | 2800 | 0.340 |
Why?
|
Methotrexate | 7 | 2005 | 1719 | 0.310 |
Why?
|
Mastectomy, Simple | 2 | 2007 | 23 | 0.310 |
Why?
|
Heart | 6 | 2018 | 4425 | 0.270 |
Why?
|
Seroma | 1 | 2007 | 75 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 10384 | 0.270 |
Why?
|
Patient Compliance | 2 | 2020 | 2694 | 0.260 |
Why?
|
Middle Aged | 112 | 2024 | 223267 | 0.260 |
Why?
|
Radiosurgery | 3 | 2023 | 1330 | 0.250 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 10 | 2013 | 5389 | 0.250 |
Why?
|
Insurance, Liability | 2 | 2017 | 100 | 0.250 |
Why?
|
Aged | 94 | 2024 | 171344 | 0.240 |
Why?
|
Antineoplastic Agents | 10 | 2018 | 13644 | 0.240 |
Why?
|
Carcinoma, Lobular | 3 | 2005 | 480 | 0.240 |
Why?
|
Heart Diseases | 2 | 2017 | 2817 | 0.240 |
Why?
|
Nitriles | 1 | 2010 | 981 | 0.230 |
Why?
|
Lymphedema | 2 | 2023 | 526 | 0.230 |
Why?
|
Treatment Outcome | 44 | 2024 | 65286 | 0.230 |
Why?
|
Triazoles | 1 | 2010 | 902 | 0.230 |
Why?
|
Lung Neoplasms | 14 | 2017 | 13489 | 0.230 |
Why?
|
Markov Chains | 4 | 2020 | 974 | 0.220 |
Why?
|
Survival Rate | 22 | 2016 | 12826 | 0.220 |
Why?
|
Doxorubicin | 6 | 2012 | 2229 | 0.220 |
Why?
|
Neoplasm Invasiveness | 13 | 2018 | 3610 | 0.220 |
Why?
|
Patient Selection | 6 | 2013 | 4252 | 0.210 |
Why?
|
Particle Accelerators | 2 | 2003 | 172 | 0.210 |
Why?
|
Estrogen Antagonists | 1 | 2003 | 151 | 0.210 |
Why?
|
Survival Analysis | 22 | 2011 | 10101 | 0.200 |
Why?
|
Follow-Up Studies | 53 | 2016 | 39312 | 0.200 |
Why?
|
Disease-Free Survival | 14 | 2012 | 6853 | 0.200 |
Why?
|
Societies, Medical | 4 | 2016 | 3957 | 0.190 |
Why?
|
Age Factors | 17 | 2020 | 18397 | 0.190 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2017 | 1673 | 0.180 |
Why?
|
Malpractice | 2 | 2017 | 561 | 0.180 |
Why?
|
Postoperative Complications | 5 | 2019 | 15831 | 0.180 |
Why?
|
Pneumonectomy | 6 | 2013 | 1147 | 0.180 |
Why?
|
United States | 19 | 2021 | 72945 | 0.180 |
Why?
|
Medical Oncology | 3 | 2016 | 2340 | 0.170 |
Why?
|
Neoplasms, Second Primary | 7 | 2012 | 1062 | 0.170 |
Why?
|
Aged, 80 and over | 41 | 2021 | 59548 | 0.170 |
Why?
|
Adult | 88 | 2024 | 223305 | 0.170 |
Why?
|
Postoperative Care | 2 | 2003 | 1480 | 0.170 |
Why?
|
Phyllodes Tumor | 1 | 2019 | 55 | 0.170 |
Why?
|
Prognosis | 36 | 2015 | 29959 | 0.160 |
Why?
|
Mediastinum | 3 | 2017 | 272 | 0.160 |
Why?
|
Neoplasms, Multiple Primary | 6 | 2000 | 594 | 0.160 |
Why?
|
Treatment Failure | 11 | 2010 | 2659 | 0.160 |
Why?
|
Receptors, Estrogen | 8 | 2021 | 2252 | 0.160 |
Why?
|
Cost-Benefit Analysis | 6 | 2022 | 5536 | 0.160 |
Why?
|
Adenocarcinoma | 12 | 2012 | 6359 | 0.160 |
Why?
|
Spinal Cord Compression | 1 | 2020 | 234 | 0.150 |
Why?
|
Pneumonia | 2 | 2009 | 2161 | 0.150 |
Why?
|
Ontario | 1 | 2019 | 403 | 0.150 |
Why?
|
Prospective Studies | 23 | 2023 | 54872 | 0.150 |
Why?
|
United States Food and Drug Administration | 2 | 2017 | 1673 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 1998 | 646 | 0.150 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5367 | 0.150 |
Why?
|
Antidotes | 1 | 1998 | 138 | 0.150 |
Why?
|
Receptor, erbB-2 | 4 | 2023 | 2598 | 0.140 |
Why?
|
Decision Support Techniques | 4 | 2021 | 2007 | 0.140 |
Why?
|
Medical Device Recalls | 1 | 2017 | 15 | 0.140 |
Why?
|
Age of Onset | 1 | 2004 | 3343 | 0.140 |
Why?
|
Retrospective Studies | 43 | 2019 | 81657 | 0.140 |
Why?
|
Rectal Neoplasms | 6 | 1998 | 1183 | 0.140 |
Why?
|
Heartburn | 1 | 2017 | 71 | 0.140 |
Why?
|
Time Factors | 22 | 2017 | 40149 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2016 | 877 | 0.130 |
Why?
|
Leucovorin | 1 | 1998 | 644 | 0.130 |
Why?
|
Organs at Risk | 1 | 2018 | 367 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2011 | 454 | 0.130 |
Why?
|
Lung | 3 | 2012 | 10068 | 0.130 |
Why?
|
Clinical Trials as Topic | 10 | 2019 | 8045 | 0.130 |
Why?
|
Equipment Safety | 1 | 2017 | 250 | 0.130 |
Why?
|
Standard of Care | 1 | 2020 | 569 | 0.130 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 2131 | 0.130 |
Why?
|
Decision Making | 4 | 2021 | 3951 | 0.130 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2017 | 463 | 0.120 |
Why?
|
Electrons | 4 | 2006 | 264 | 0.120 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2001 | 542 | 0.120 |
Why?
|
Radiotherapy, High-Energy | 4 | 1992 | 228 | 0.120 |
Why?
|
Neoplasm Metastasis | 9 | 2009 | 4892 | 0.120 |
Why?
|
Adenocarcinoma, Mucinous | 7 | 2006 | 523 | 0.120 |
Why?
|
Rheumatic Diseases | 1 | 2001 | 657 | 0.120 |
Why?
|
Carcinoma | 3 | 1998 | 2325 | 0.120 |
Why?
|
China | 1 | 2020 | 2386 | 0.110 |
Why?
|
Equipment Failure Analysis | 1 | 2017 | 832 | 0.110 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2020 | 798 | 0.110 |
Why?
|
Microsurgery | 1 | 2019 | 798 | 0.110 |
Why?
|
Carcinoma, Large Cell | 2 | 2011 | 114 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3692 | 0.100 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 3431 | 0.100 |
Why?
|
Photons | 2 | 2014 | 591 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2353 | 0.100 |
Why?
|
Salvage Therapy | 7 | 2019 | 1274 | 0.100 |
Why?
|
Medical Errors | 2 | 2017 | 1260 | 0.100 |
Why?
|
Life Expectancy | 1 | 2018 | 1248 | 0.090 |
Why?
|
Incidence | 12 | 2019 | 21527 | 0.090 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 550 | 0.090 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2009 | 83 | 0.090 |
Why?
|
Pain | 2 | 2023 | 5098 | 0.090 |
Why?
|
Paget's Disease, Mammary | 2 | 2003 | 18 | 0.090 |
Why?
|
Palliative Care | 2 | 2023 | 3640 | 0.090 |
Why?
|
Actuarial Analysis | 8 | 1996 | 370 | 0.090 |
Why?
|
Posture | 2 | 2006 | 955 | 0.090 |
Why?
|
Risk Factors | 23 | 2018 | 74889 | 0.080 |
Why?
|
Esthetics | 6 | 2006 | 328 | 0.080 |
Why?
|
Databases, Factual | 4 | 2020 | 8065 | 0.080 |
Why?
|
Radiation Dosage | 3 | 2009 | 1958 | 0.080 |
Why?
|
Risk Assessment | 7 | 2016 | 24299 | 0.080 |
Why?
|
Fractures, Bone | 1 | 2020 | 2043 | 0.080 |
Why?
|
Tumor Burden | 4 | 2018 | 1902 | 0.080 |
Why?
|
Diabetes Complications | 2 | 2013 | 1319 | 0.070 |
Why?
|
Lymphoma | 2 | 2017 | 1899 | 0.070 |
Why?
|
Esophageal Neoplasms | 2 | 1995 | 1661 | 0.070 |
Why?
|
Lymphatic System | 1 | 1989 | 250 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2016 | 9528 | 0.070 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2011 | 343 | 0.070 |
Why?
|
Quality of Life | 2 | 2024 | 13476 | 0.060 |
Why?
|
Software | 2 | 2017 | 4464 | 0.060 |
Why?
|
Death Certificates | 1 | 2006 | 172 | 0.060 |
Why?
|
Barrett Esophagus | 1 | 2008 | 494 | 0.060 |
Why?
|
Sigmoid Neoplasms | 3 | 1989 | 55 | 0.060 |
Why?
|
Carcinoma, Medullary | 1 | 2004 | 115 | 0.050 |
Why?
|
Manuals as Topic | 1 | 2003 | 99 | 0.050 |
Why?
|
Proportional Hazards Models | 7 | 2015 | 12536 | 0.050 |
Why?
|
Drug Therapy | 1 | 2006 | 504 | 0.050 |
Why?
|
Multivariate Analysis | 8 | 2015 | 12064 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2010 | 22248 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 1740 | 0.050 |
Why?
|
Advisory Committees | 2 | 2006 | 797 | 0.050 |
Why?
|
Tattooing | 1 | 2003 | 57 | 0.050 |
Why?
|
Biopsy | 6 | 2009 | 6779 | 0.050 |
Why?
|
Linear Models | 3 | 2017 | 5873 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2000 | 1733 | 0.050 |
Why?
|
Male | 27 | 2021 | 364154 | 0.050 |
Why?
|
Mathematics | 1 | 2003 | 696 | 0.050 |
Why?
|
Arm | 3 | 1999 | 591 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 1994 | 2058 | 0.050 |
Why?
|
Surgical Flaps | 1 | 2010 | 1680 | 0.050 |
Why?
|
Scattering, Radiation | 1 | 2003 | 483 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6514 | 0.050 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2846 | 0.050 |
Why?
|
Mesothelioma | 3 | 1997 | 774 | 0.050 |
Why?
|
Telangiectasis | 2 | 2014 | 78 | 0.040 |
Why?
|
Breast Implants | 1 | 2024 | 414 | 0.040 |
Why?
|
Dactinomycin | 1 | 2001 | 304 | 0.040 |
Why?
|
Edema | 3 | 1999 | 764 | 0.040 |
Why?
|
Career Choice | 1 | 2007 | 768 | 0.040 |
Why?
|
Skin | 1 | 2014 | 4499 | 0.040 |
Why?
|
Laryngeal Neoplasms | 1 | 1984 | 514 | 0.040 |
Why?
|
Prevalence | 1 | 2017 | 15835 | 0.040 |
Why?
|
Teaching | 1 | 2007 | 1171 | 0.040 |
Why?
|
Logistic Models | 4 | 2017 | 13276 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 866 | 0.040 |
Why?
|
Preoperative Care | 2 | 1998 | 2253 | 0.040 |
Why?
|
Fluoroscopy | 1 | 2003 | 948 | 0.040 |
Why?
|
Genes, erbB-2 | 1 | 2019 | 161 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11062 | 0.040 |
Why?
|
Faculty, Medical | 1 | 2007 | 1226 | 0.040 |
Why?
|
Rectum | 2 | 1997 | 897 | 0.040 |
Why?
|
Neoadjuvant Therapy | 3 | 2012 | 2902 | 0.040 |
Why?
|
Risk | 4 | 2019 | 9602 | 0.040 |
Why?
|
Mammography | 5 | 2009 | 2429 | 0.040 |
Why?
|
Relative Biological Effectiveness | 1 | 2019 | 313 | 0.040 |
Why?
|
Recurrence | 4 | 2010 | 8507 | 0.040 |
Why?
|
Product Recalls and Withdrawals | 1 | 2017 | 7 | 0.040 |
Why?
|
Technology, Radiologic | 1 | 2017 | 158 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2001 | 910 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 1998 | 476 | 0.030 |
Why?
|
Models, Economic | 1 | 2020 | 719 | 0.030 |
Why?
|
Mediastinal Neoplasms | 2 | 2010 | 403 | 0.030 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2016 | 187 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 4853 | 0.030 |
Why?
|
Device Approval | 1 | 2017 | 164 | 0.030 |
Why?
|
Equipment Design | 1 | 2003 | 3488 | 0.030 |
Why?
|
Mass Screening | 2 | 2009 | 5454 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2007 | 3698 | 0.030 |
Why?
|
Etanidazole | 1 | 1994 | 22 | 0.030 |
Why?
|
Cosmetics | 1 | 1996 | 104 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2003 | 2474 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 2017 | 273 | 0.030 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1994 | 36 | 0.030 |
Why?
|
Fat Necrosis | 1 | 2014 | 60 | 0.030 |
Why?
|
Radiodermatitis | 1 | 2014 | 61 | 0.030 |
Why?
|
Postmenopause | 1 | 2003 | 2517 | 0.030 |
Why?
|
Thiophenes | 1 | 1998 | 570 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2476 | 0.030 |
Why?
|
Forecasting | 2 | 2012 | 2936 | 0.030 |
Why?
|
Primary Ovarian Insufficiency | 1 | 1994 | 104 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 2013 | 285 | 0.030 |
Why?
|
Medicare | 2 | 2021 | 6813 | 0.020 |
Why?
|
Skin Pigmentation | 1 | 2014 | 278 | 0.020 |
Why?
|
Pleural Neoplasms | 1 | 1997 | 584 | 0.020 |
Why?
|
Quinazolines | 1 | 1998 | 1367 | 0.020 |
Why?
|
Colonic Neoplasms | 3 | 1988 | 2535 | 0.020 |
Why?
|
Colorectal Neoplasms | 2 | 2002 | 6965 | 0.020 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 1012 | 0.020 |
Why?
|
Registries | 2 | 2006 | 8352 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2016 | 750 | 0.020 |
Why?
|
Peritoneal Neoplasms | 2 | 1988 | 706 | 0.020 |
Why?
|
Comorbidity | 1 | 2005 | 10580 | 0.020 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 15 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 1992 | 445 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2274 | 0.020 |
Why?
|
Feasibility Studies | 3 | 2014 | 5306 | 0.020 |
Why?
|
Cricetinae | 1 | 1993 | 2416 | 0.020 |
Why?
|
Palpation | 1 | 2009 | 166 | 0.020 |
Why?
|
Vinblastine | 1 | 2010 | 482 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2334 | 0.020 |
Why?
|
Clavicle | 1 | 1991 | 224 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2009 | 4050 | 0.020 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2002 | 7841 | 0.020 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 1988 | 63 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1994 | 713 | 0.020 |
Why?
|
Cisplatin | 2 | 2010 | 1656 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 3 | 2011 | 36570 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 3138 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1998 | 3723 | 0.020 |
Why?
|
Sarcoma | 2 | 2002 | 1802 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5922 | 0.020 |
Why?
|
Colon, Sigmoid | 1 | 1988 | 124 | 0.020 |
Why?
|
Necrosis | 2 | 1992 | 1614 | 0.020 |
Why?
|
Europe | 2 | 1996 | 3430 | 0.020 |
Why?
|
Ultrasonography, Mammary | 1 | 2009 | 243 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1622 | 0.020 |
Why?
|
Carboplatin | 1 | 2010 | 790 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 1159 | 0.020 |
Why?
|
Phosphorus Radioisotopes | 1 | 1987 | 100 | 0.020 |
Why?
|
Radionuclide Imaging | 2 | 1988 | 1986 | 0.020 |
Why?
|
Medicine | 1 | 2015 | 944 | 0.020 |
Why?
|
Cohort Studies | 6 | 2011 | 41706 | 0.020 |
Why?
|
Esophagoscopy | 1 | 2008 | 398 | 0.020 |
Why?
|
Internship and Residency | 1 | 2007 | 5943 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1972 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1995 | 1659 | 0.010 |
Why?
|
Poisson Distribution | 1 | 2006 | 507 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2003 | 20146 | 0.010 |
Why?
|
Specimen Handling | 1 | 2009 | 706 | 0.010 |
Why?
|
Craniopharyngioma | 1 | 1987 | 279 | 0.010 |
Why?
|
Career Mobility | 1 | 2007 | 262 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4056 | 0.010 |
Why?
|
Endometrial Neoplasms | 1 | 1994 | 1381 | 0.010 |
Why?
|
Epithelium | 1 | 2008 | 1606 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9346 | 0.010 |
Why?
|
Regression Analysis | 3 | 2000 | 6329 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 1994 | 2631 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 3 | 2003 | 20710 | 0.010 |
Why?
|
Paclitaxel | 1 | 2010 | 1728 | 0.010 |
Why?
|
Methods | 2 | 1997 | 1065 | 0.010 |
Why?
|
Esophagus | 1 | 2008 | 1040 | 0.010 |
Why?
|
Surgery, Plastic | 1 | 1989 | 652 | 0.010 |
Why?
|
Glottis | 1 | 1984 | 214 | 0.010 |
Why?
|
Blood Vessels | 1 | 1988 | 1111 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4668 | 0.010 |
Why?
|
Mentors | 1 | 2007 | 671 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2005 | 1615 | 0.010 |
Why?
|
Vocal Cords | 1 | 1984 | 520 | 0.010 |
Why?
|
Length of Stay | 1 | 2013 | 6491 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6258 | 0.010 |
Why?
|
Analysis of Variance | 2 | 2000 | 6214 | 0.010 |
Why?
|
International Cooperation | 1 | 2005 | 1434 | 0.010 |
Why?
|
Pituitary Neoplasms | 1 | 1987 | 1324 | 0.010 |
Why?
|
Thymidylate Synthase | 1 | 1998 | 74 | 0.010 |
Why?
|
Neoplasms | 2 | 2017 | 22350 | 0.010 |
Why?
|
HT29 Cells | 1 | 1998 | 187 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5860 | 0.010 |
Why?
|
Carcinoma, Lewis Lung | 1 | 1998 | 106 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1994 | 3633 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3235 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1998 | 11514 | 0.010 |
Why?
|
Health Care Costs | 1 | 2009 | 3240 | 0.010 |
Why?
|
Abdominal Neoplasms | 1 | 1997 | 286 | 0.010 |
Why?
|
Pilot Projects | 2 | 1999 | 8728 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1998 | 2012 | 0.010 |
Why?
|
Thoracic Neoplasms | 1 | 1997 | 269 | 0.010 |
Why?
|
Heart Failure | 1 | 1998 | 11879 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 26309 | 0.010 |
Why?
|
Drug Interactions | 1 | 1998 | 1419 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 13050 | 0.010 |
Why?
|
Young Adult | 2 | 2011 | 59939 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 8623 | 0.010 |
Why?
|
Ovarian Neoplasms | 2 | 2002 | 4903 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 5888 | 0.010 |
Why?
|
Ovariectomy | 1 | 1994 | 612 | 0.010 |
Why?
|
Survivors | 1 | 2002 | 2379 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2006 | 4968 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1998 | 6105 | 0.010 |
Why?
|
Rib Fractures | 1 | 1992 | 124 | 0.010 |
Why?
|
Pericarditis | 1 | 1992 | 136 | 0.010 |
Why?
|
Family Health | 1 | 1995 | 1254 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 1998 | 2391 | 0.010 |
Why?
|
Brachial Plexus | 1 | 1992 | 171 | 0.010 |
Why?
|
Vincristine | 1 | 1991 | 1040 | 0.000 |
Why?
|
Cell Survival | 1 | 1998 | 5749 | 0.000 |
Why?
|
Odds Ratio | 1 | 2000 | 9661 | 0.000 |
Why?
|
Neck | 1 | 1992 | 736 | 0.000 |
Why?
|
Prednisone | 1 | 1991 | 1566 | 0.000 |
Why?
|
Dysgerminoma | 1 | 1986 | 66 | 0.000 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1998 | 10745 | 0.000 |
Why?
|
Animals | 2 | 1998 | 168939 | 0.000 |
Why?
|
Injections, Intravenous | 1 | 1987 | 1377 | 0.000 |
Why?
|
Head and Neck Neoplasms | 1 | 1998 | 2930 | 0.000 |
Why?
|
Predictive Value of Tests | 2 | 1990 | 15425 | 0.000 |
Why?
|
Melanoma | 1 | 2002 | 5702 | 0.000 |
Why?
|
Adolescent | 2 | 2009 | 88902 | 0.000 |
Why?
|
Random Allocation | 1 | 1987 | 2394 | 0.000 |
Why?
|
Prostheses and Implants | 1 | 1989 | 1275 | 0.000 |
Why?
|
Hand | 1 | 1987 | 910 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1987 | 2350 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 22351 | 0.000 |
Why?
|
Testicular Neoplasms | 1 | 1986 | 806 | 0.000 |
Why?
|
Emergencies | 1 | 1986 | 1223 | 0.000 |
Why?
|
Physical Examination | 1 | 1985 | 1265 | 0.000 |
Why?
|
Disease Progression | 1 | 1995 | 13642 | 0.000 |
Why?
|
Reoperation | 1 | 1987 | 4325 | 0.000 |
Why?
|
Radiography | 1 | 1987 | 6968 | 0.000 |
Why?
|
Mice | 1 | 1998 | 81898 | 0.000 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1988 | 8928 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1986 | 12985 | 0.000 |
Why?
|
Child, Preschool | 1 | 1986 | 42577 | 0.000 |
Why?
|
Child | 1 | 1986 | 80670 | 0.000 |
Why?
|